Campuses: FH.com Home button

Clinical Trials Currently Open

Below is the list of clinical trials currently available at the Cancer Institute of Florida Hospital Memorial Medical Center.
For any questions or to learn if you qualify for a trial, please contact our clinical trial research coordinator at (386) 231-4023.

Clinical trials with Florida Cancer Specialists can be found at www.flcancer.com/trialnavigator

 

Breast Cancer Studies

BCCR/iCaRe2:    Integrated Cancer Repository for Cancer Research (iCaRe2)” (NCT02012699)
Formerly entitled:   Breast Cancer Collaborative Registry Trial (BCCR):  A Breast Cancer Information Registry for Participants with Breast Cancer or Characteristics of Hereditary Breast Cancer NCT02012699 (FHMMC, Flagler, FISH, Deland)   https://clinicaltrials.gov/ct2/show/NCT02012699

BRE 257/FCS:   A Double-blind Study of Paclitaxel in Combination with Reparixin or Placebo for Metastatic Triple-Negative Breast Cancer-NCT02370238 https://clinicaltrials.gov/ct2/show/NCT02370238

BRE 271/FCS:   A Phase 2 Randomized, Double-Blinded, Controlled Study of ONT-380 vs Placebo in Combination with Capecitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma (HER2CLIMB) NCT02614794 https://clinicaltrials.gov/ct2/show/NCT02614794

BRE 283/FCS:   A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine (ATTAIN) NCT02915744   https://clinicaltrials.gov/ct2/show/NCT02915744

BRE 298 - IMMU-132-05 An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan versus Treatment of Physician Choice in Patients with Metastatic (Stage IV) Triple-Negative Breast Cancer Who Received At least Two Prior Treatments NCT02574455  https://clinicaltrials.gov/ct2/show/NCT02574455

BRE 303 - ODO-TE-B301 Tesetaxel Plus Reduced Dose of Capecitabine vs. Capecitabine in HER2 Negative, HR Positive, MBC NCT03326674  https://www.clinicaltrials.gov/ct2/show/NCT03326674

Lung Studies

LUN 358 A prospective, randomized, multicenter, open-label, comparative global phase 3 study to determine the efficacy, safety and tolerability of durvalumab or durvalumab + tremelimumab in combination therapy with platinum based chemotherapy for the first line treatment of patients with metastatic non-small cell lung cancer  NCT03164616  https://clinicaltrials.gov/ct2/show/NCT03164616

Lymphoma Studies

LYM 120 - UTX-TGR-phase 2b randomized study to assess the efficacy and safety of the combination of  ublituximab + TGR-1202 with or without bendamustine and TGR-1202 alone in patients with previously treated non-Hodgkin’s lymphoma  NCT02793583 https://clinicaltrials.gov/ct2/show/NCT02793583

LYM 122 - ACE-LY-308 A phase 3, randomized, double blind, placebo controlled, multicenter study of BR alone versus in combination with Acalabrutinib (ACP-196) in subjects with previously untreated mantle cell Lymphoma NCT02972840   https://clinicaltrials.gov/ct2/show/NCT02972840

LYM 126 - PCYC - 1141-CA A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naive Subjects with Follicular Lymphoma NCT02947347   https://clinicaltrials.gov/ct2/show/NCT02947347

LYM 135 - GO39942 A Phase Iii, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing The Efficacy And Safety Of Polatuzumab Vedotin In Combination With R-Chop Versus Rituximab And Chop (R-Chop) In Previously Untreated Patients With Diffuse Large B-Cell Lymphoma (Dlbcl) NCT03274492  https://clinicaltrials.gov/ct2/show/NCT03274492

Melanoma Studies

Amgen 20120139:   "A Registry Study to Evaluate the Survival and Long-Term Safety of Subjects with Melanoma Who Previously Received Talimogene Laherparepvec."  NCT02173171 (FHMMC/Daytona Cancer Ctr.) https://clinicaltrials.gov/ct2/show/NCT02173171

MEL 55 - A phase III, open-label, multicenter, two-arm, randomized study to investigate the efficacy and safety of cobimetinib plus atezolizumab versus pembrolizumab in patients with previously untreated advanced BRAF wild-type melanoma  NCT03273153  https://clinicaltrials.gov/ct2/show/NCT03273153

 

Genitourinary

GU 115/ FCS - A Double-Blinded Placebo-Controlled Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men with Metastatic Castration Resistant Prostate Cancer NCT02407054  https://clinicaltrials.gov/ct2/show/NCT02407054

GU 137/ FCS:   Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma.   NCT02811861 https://clinicaltrials.gov/ct2/show/NCT02811861

Gastrointestinal

GI 247 - CanStem303C A Phase III Study of BBI-608 in combination with 5-Fluorouracil Leucovorin Irinotecan (FOLFIRI) in Adult Patients with Previously Treated Metastatic Colorectal Cancer (CRC) NCT02753127   https://clinicaltrials.gov/ct2/show/NCT02753127

GI 266 - BGB-290-303:  A Phase 3, Double-blind, Randomized Study of BGB-290 (PARP inhibitor) versus Placebo as Maintenance Therapy in Patients with Inoperable Locally Advanced or Metastatic Gastric Cancer that Responded to Platinum-based First-line Chemotherapy NCT03427814  https://clinicaltrials.gov/ct2/show/NCT03427814

Ovarian Studies

GYN 57/FCS:   Phase 2 Study of MLN0128, Combination of MLN0128 with MLN1117, Paclitaxel and Combination of MLN0128 with Paclitaxel in Women with Endometrial Cancer NCT02725268 https://clinicaltrials.gov/ct2/show/NCT02725268

GYN 63 - A Phase II Open-Label Study to Assess the Safety, Pharmacokinetics and Clinical Activity of Acelarin® (NUC-1031) Given on Days 1, 8 and 15 of a 28-Day Schedule in Patients with Recurrent Platinum-Resistant Ovarian Cancer NCT03146663  https://clinicaltrials.gov/ct2/show/NCT03146663

GYN 80 - DEK-DKK1-P204: A Phase 2 Study Evaluating the Efficacy and Safety of DKN-01 (humanized monoclonal antibody to DKK1 ) as a Monotherapy or in Combination with Paclitaxel in Patients With Relapsed/ Refractory Endometrioid Endometrial or Endometrioid Ovarian Cancer NCT03395080   https://clinicaltrials.gov/ct2/show/NCT03395080

 

Other Cancer Types

MULTI 12/FCS:   An Open Label Phase II Multi-Cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (NCT 02832167). https://clinicaltrials.gov/ct2/show/NCT02795156

PRO 10/FCS:   Study to Assess the Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations (NCT02795156) https://clinicaltrials.gov/ct2/show/NCT02795156

MM74/FCS:  An Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Participants NCT02761187  https://clinicaltrials.gov/ct2/show/NCT02761187

MPN 09 - PAC203 An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients with Primary Myelofibrosis Previously Treated with Ruxolitinib NCT03165734  https://clinicaltrials.gov/ct2/show/NCT03165734

Please Contact Our Research Office if You Are Interested in Learning More About Clinical Trials:

224 Memorial Medical Parkway
Daytona Beach, FL 32117
 

Sandy Allten, RN, OCN, CCRP
sandra.allten@fhmmc.org
Phone: 386-231-4023

Catherine McQuade, RN, BSN
FCS Trials: cmcquade@flcancer.com
Phone: 386-231-4067